Zobrazeno 1 - 10
of 444
pro vyhledávání: '"Checkpoint blockers"'
Autor:
Yichun Zeng, Liying Zhang, Yichen Liang, Xian Zhang, Lei Li, Maoqi Wang, Jingliang Guo, Qiuxian Li, Jin Cao, Juan J. Gu, Buhai Wang
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 13928-13941 (2023)
Abstract Background Currently, immune checkpoint blockers (ICB) and radiotherapy (RT) combination therapy is broadly applied in non‐small cell lung cancer (NSCLC) patients. However, meta‐analysis about safety and efficacy of RT + ICB versus ICB h
Externí odkaz:
https://doaj.org/article/302bb34d569445298a091f62ee3d33bd
Autor:
Jenny Sprooten, Raquel S. Laureano, Isaure Vanmeerbeek, Jannes Govaerts, Stefan Naulaerts, Daniel M. Borras, Lisa Kinget, Jitka Fucíková, Radek Špíšek, Lenka Palová Jelínková, Oliver Kepp, Guido Kroemer, Dmitri V. Krysko, An Coosemans, Rianne D.W. Vaes, Dirk De Ruysscher, Steven De Vleeschouwer, Els Wauters, Evelien Smits, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, Hans Wildiers, Paul M. Clement, Peter Vandenabeele, Laurence Zitvogel, Abhishek D. Garg
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTImmunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell death that activates, rather than suppresses, innate and adaptive immune responses. Such responses culminate into T cell-driven immunity against anti
Externí odkaz:
https://doaj.org/article/7008e019d7c247f4ac120beabac8edc7
Autor:
Julie Le Naour, Guido Kroemer
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTAccumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological
Externí odkaz:
https://doaj.org/article/3cf8d0ddd2c24965a615ff900bee09dc
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Ferroptosis is an iron-dependent programmed cell death process, and studies have confirmed that it plays an important regulatory role in the occurrence and development of various malignancies including hepatocellular carcinoma (HCC). In a
Externí odkaz:
https://doaj.org/article/98066c177034408fb8ed47374304e81c
Autor:
Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, an Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I Jolanda M de Vries, Yanling Xiao, Abhishek D Garg
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobili
Externí odkaz:
https://doaj.org/article/be78d83094d145fe958410723c8c8404
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background Gastric cancer (GC) is a globally prevalent cancer, ranking fifth for incidence and fourth for mortality worldwide. The N6-methyladenosine (m6A) related long noncoding RNAs (lncRNAs) were widely investigated in recent studies. Nev
Externí odkaz:
https://doaj.org/article/78d36a118bdd4beb8a3f255a4aab436f
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 48-63 (2021)
With an increasing number of alternative effective therapies available for patients, there is an increasing need for a more accurate selection for therapy (compared to observation, for example, after radical surgical treatment), selection of the opti
Externí odkaz:
https://doaj.org/article/8ae0fa990e5041159cac2443cdd966c9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Roukiah Khalil, Ryan J. Green, Kavya Sivakumar, Payal Varandani, Srinivas Bharadwaj, Shyam S. Mohapatra, Subhra Mohapatra
Publikováno v:
Cancers, Vol 15, Iss 12, p 3089 (2023)
Treatment of late-stage lung cancers remains challenging with a five-year survival rate of 8%. Immune checkpoint blockers (ICBs) revolutionized the treatment of non-small cell lung cancer (NSCLC) by reactivating anti-tumor immunity. Despite achieving
Externí odkaz:
https://doaj.org/article/699d4cd775b9429f90dc396e1e5be62f